Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imiquimod and quadrivalent HPV vaccine in MSM with HIV and anal high-risk HPV
ACTRN12617001355369Phase 2Completed
- Sponsor
- Alfred Health
- Start
- Apr 2018
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imiquimod and quadrivalent human papillomavirus vaccine in human papillomavirus infection, sponsored by Alfred Health. Primary endpoints: Tolerability of imiquimod intervention, Health-related quality of life and 1 more. Started Apr 2018; status: completed.
02
Drugs
imiquimodquadrivalent human papillomavirus vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on ACTRN12617001355369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001355369.